Tests antibiotics in people with acute heart attacks
Tests whether antibiotics can reduce serious heart events in adults with acute heart attacks.
Key facts
- Who runs it
- TAYS Sydaenkeskus Oy
- Where
- Tampere, FinlandSee the site
- Trial code
- Registry title
- Antibiotic Treatment Trial in Acute Coronary Syndrome
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 1,070 people, planned
- Started
- 1 Nov 2025
- Expected to end
- 31 Dec 2034
- Type of study
- Interventional
- Record updated
- 27 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have had a heart attack (STEMI or NSTEMI), are having an angiography, and have several heart risk factors. It tests whether antibiotic treatment lowers later heart events.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- A clinically diagnosed heart attack, either STEMI or NSTEMI, with an invasive strategy chosen, meaning angiography is performed
- Earlier treatment
- People on on-going antibiotic therapy or on-going methotrexate medication cannot join
Main reasons for not taking part
- Cardiogenic shock
- Pregnancy
- Severe valvular disease
- On-going bleeding or very high bleeding risk
- Allergy to cephalosporin
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Clinically diagnosed ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)
- Invasive strategy has been chosen, i.e. angiography is performed
- Age ≥18 years
- Informed consent has been obtained
- at least 3 of following high risk criteria are met (hypertension, DM, moderate renal insufficiency eGFR<60ml/min, peripheral arterial disease ASO, multivessel coronary artery disease, previous myocardial infraction, previous stroke or TIA)
Who cannot take part
- On-going methotrexate medication
- On-going antibiotic therapy
- Clinical diagnosis of Takotsubo syndrome
- Severe valvular disease
- On-going bleeding or very high bleeding risk
- Severe allergy to contrast agents or ASA
- Allergy to cephalosporin
- Cardiogenic shock
- Pregnancy
- Probable finding of SCAD (spontaneous coronary dissection)
- Definite coronary embolism
- < 1 year life expectancy
Where in Finland
- TAYS Sydaenkeskus OyTampere, FinlandNot yet recruiting
About the trial
What the trial wants to find out
To assess whether the number of clinical endpoints (MACCE) can be reduced by antibiotic treatment, targeting mainly bacteria that have in previous studies been shown to be involved in complex atherosclerotic plaques, such as those found in patients suffering from acute myocardial infarction.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Antibiotic Treatment Trial in Acute Coronary Syndrome
- Plain-language title
- Tests antibiotics in people with acute heart attacksGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 27 August 2025